1. Home
  2. Directory
  3. New Hampshire
  4. Dover
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1376809277

DR. DONIELLE F SLIWA MD, MPH
Prescription History 1376809277
Internal Medicine - Medical Oncology in Dover, NH

NPI Status: Active since April 04, 2012

Contact Information

789 CENTRAL AVE
DOVER, NH
ZIP 03820
Phone: (603) 742-8787

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DONIELLE F SLIWA MD, MPH, an active Medical Oncology specialist practicing in Dover, NH. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 155 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 64 claims alone.

Medication Index

A
E
L
P
T
V
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 64
30-Day Fills 181.2
Days Supply 5,431
NH State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills123.7
Peer Average Days Supply3,683
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.0% more claims than the standard regional baseline profile for NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,249.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.15

State Avg Cost Per Claim

$26.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Eliquis

Generic Formulation: ApixabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 23.0
Days Supply 690
NH State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills99.6
Peer Average Days Supply2,813
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.6% less volume than the regional standard for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,375.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,028.91

State Avg Cost Per Claim

$862.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Letrozole

Generic Formulation: LetrozoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 22
30-Day Fills 65.0
Days Supply 1,950
NH State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills116.1
Peer Average Days Supply3,475
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.2% less volume than the regional standard for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $955.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.43

State Avg Cost Per Claim

$32.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Prednisone

Generic Formulation: PrednisoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 15
30-Day Fills 20.0
Days Supply 595
NH State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills48.6
Peer Average Days Supply938
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.5% less volume than the regional standard for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $144.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.65

State Avg Cost Per Claim

$7.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 29
30-Day Fills 88.3
Days Supply 2,650
NH State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills75.1
Peer Average Days Supply2,249
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,614.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$55.69

State Avg Cost Per Claim

$37.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Verzenio

Generic Formulation: AbemaciclibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
NH State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.6
Peer Average Days Supply520
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside NH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $183,299.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,274.92

State Avg Cost Per Claim

$14,726.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DONIELLE F SLIWA MD, MPH provides transparency into local medical care patterns within Dover, NH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.